Author:
Gratzke Christian,van Maanen Rob,Chapple Christopher,Abrams Paul,Herschorn Sender,Robinson Dudley,Ridder Arwin,Stoelzel Matthias,Paireddy Asha,Yoon Sang Jin,Al-Shukri Salman,Rechberger Tomasz,Mueller Elizabeth R.
Reference17 articles.
1. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013;Drake;Neurourol Urodyn,2014
2. Antimuscarinics and overactive bladder: other mechanism of action;Yamaguchi;Neurourol Urodyn,2010
3. Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function;Takasu;J Pharmacol Exp Ther,2007
4. Evaluation of the pharmacokinetic interaction between the β3-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects;Krauwinkel;Clin Pharmacol Drug Dev,2013
5. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony);Abrams;Eur Urol,2015
Cited by
76 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献